Examples of using Decentralised procedure in English and their translations into Finnish
{-}
-
Medicine
-
Official
-
Colloquial
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
Chapter 4 Mutual recognition and decentralised procedure.
The Decentralised Procedure, SE/ H/ 575/ 07/ DC, started on 1 September 2006.
The original Article 6 setting up a decentralised procedure is deleted.
The Decentralised Procedure UK/ H/ 0892/ 01/ DC started on 12 April 2006.
Mutual recognition procedure and decentralised procedure.
Decentralised procedure: 210 says+ 30 days for the review of translations.
The application fee for a national procedure, mutual recognition procedure and decentralised procedure must be paid to Fimea.
The decentralised procedure and the mutual recognition procedure Chapter 4.
This will simplify the procedures for applying for a marketing authorisation for generic versions of these reference medicinal products under the mutual recognition or decentralised procedure.
The decentralised procedure should be replaced by a centralised procedure at EU level.
Paragraphs 1 and 2 shall not apply to veterinary medicinal products that have been authorised through a mutual recognition or decentralised procedure before the date of the application of this Regulation.
The decentralised procedure(DCP) is used to apply for market authorisation for products not authorised in any EU member state.
Lastly, it is proposed that the coordination between Member States for the pharmacovigilance of medicinal products subject to the mutual recognition or decentralised procedure be improved Article 1045.
The decentralised procedure applies in cases where a medicine has not received a marketing authorisation in any Member State.
This cooperation process should be formalised by setting up a coordination group for this procedure andby defining its operation so as to settle disagreements within the framework of a revised decentralised procedure.
In August 2006 a Decentralised Procedure started with The Netherlands as Reference Member State and thirteen Concerned Member States.
Wherever it is proposed to change the scope of the centralised procedure, it should no longer be possible to opt for the mutual-recognition or decentralised procedure in respect of new active substances.
In the new proposal, the Commission is abolishing the decentralised procedure, which was criticised for imposing a heavy administrative burden and promoting a degree of fragmentation of the internal market.
Some Members will say that the centralised procedure is costly for SMEs, butin the case of enlargement, the cost of 25 applications for market authorisation using the decentralised procedure will be much higher.
Applicants pursuing an authorisation under the decentralised procedure will be compelled to enter arbitration proceedings if an issue cannot be resolved by the Member States concerned in the case of veterinary medicinal products.
Marketing authorisation holders(including large multi-nationals, SMEs, manufacturers of generics, non prescription and veterinary medicines from different Member States)who had used the decentralised procedure;
Similarly, the mutual-recognition or decentralised procedure should be available as an option for medicinal products which represent a therapeutic innovation or which are of benefit to Society or to patients.
Similarly, we are refusing to reduce the time spent on the scientific evaluation of medicinal products, under the centralised procedure as well as the decentralised procedure, and even in the case of the accelerated procedure or the reduction protocol that we support.
The decentralised procedure was acknowledged as having significant advantages in terms of optionality but any such advantage is tempered to an extent by the failure of the system to operate on the basis of effective mutual recognition involving a significant number of Member States.
The protection period agreed in the current compromise, of eight years, plus two, plus one, for the centralised and the decentralised procedure, ensures, firstly, that there is an incentive to carry out research, and secondly, that the further development of proven active substances is rewarded.
The decentralised procedure is not adequate for authorisation of medicinal products containing new active substances, taking into consideration the high costs for their development as well as the effects on society when those products are only placed on the market of a limited number of Member States.
In response to question 1, the applicant provided a copy of the original dossier as submitted in support of the application of a decentralised procedure, and the supplementary data submitted during the decentralised procedure in response to the phase I and phase II assessment and the referral procedure in CMD(v) thereafter.
Directive 93/39 established, with effect from 1 January 1995, a decentralised procedure for mutual recognition of national marketing authorisations, together with binding arbitration by the Community in the event of disagreement between Member States see Article 4, second paragraph, subparagraph 11, Article 7(2) and 7(a) of Directive 65/65 and Articles 8 to 15c of Directive 75/319.
In response to question 1, the applicant provided a copy of the original dossier as submitted in support of the application of a decentralised procedure, and any supplementary data submitted during the decentralised procedure in response to the phase I and phase II assessment and the referral procedure in CMD(v) thereafter.
For the latter category the initial proposal included two different procedures:(a) a decentralised procedure, whereby a procuring entity would be allowed to exclude a tender after seeking the Commission's approval; and(b) a centralised procedure, with the Commission playing a central role investigation, negotiation with the third country, decision to adopt restrictive measures- a market closure or a price penalty- if necessary, which would then be applied by the national authorities in their procurement procedures. .